AbbVie's Mavyret Is First 8-Week Pan-Genotypic Combination For HCV

Aug 03 2017

• By Jessica Merrill

Listen to this article

FDA approval of the glecaprevir/pibrentasvir combination could help AbbVie fill a gap resulting from declining sales of Viekira Pak, while challenging Gilead's monopoly in some segments of the market.

AbbVie Inc.'s next-generation combination therapy for hepatitis C, Mavyret (glecaprevir/pibrentasvir), will be the first eight-week regimen to treat all non-cirrhotic genotypes of the virus, narrowing the treatment window from what previously was 12 weeks. Marvyret could help AbbVie fill a gap left by declining sales of its first HCV combination Viekira Pak and challenge rival Gilead Sciences Inc.'s near-monopoly, particularly in genotypes 2 and 3 of the virus.

FDA announced the approval of Mavyret Aug. 3 to treat HCV virus genotypes 1-6 without cirrhosis or with mild cirrhosis...

More from Anti-infective

Scrip Data Article Without An Author
Nov 19 2025
"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."
In Brief: PolyPid’s D-PLEX100 Aces Phase III Trial, US Partner, Submission Eyed
Nov 02 2025
PolyPid's D-PLEX100 meets Phase III endpoints this time around, significantly reducing surgical point infections in abdominal colorectal surgery, and is set for a US approval submission early next year.
Bavarian Nordic Well Placed To Meet Mpox Vaccine Demand
Mar 10 2025
• By Andrew McConaghie
The company will ramp up manufacturing of its Jynneos vaccine to meet demand in worst-affected African countries and stockpiling richer nations.
Cagrisema Leads The Charge For 2025
Mar 10 2025
• By Elizabeth Cairns
2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.

More from Therapeutic Category

Scrip Data Article Without An Author
Nov 19 2025
"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."
Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]
Nov 12 2025
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC
Nov 12 2025
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.